Cancer-stimulated mesenchymal stem cells create a carcinoma stem-cell niche via Prostaglandin E2 signaling

Hua-Jung Li1, Ferenc Reinhardt1, Harvey R. Herschman2 and Robert A. Weinberg1,3,4

(1) Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
(2) Departments of Biological Chemistry and Pharmacology, Molecular Biology Institute, and Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA
(3) Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
(4) MIT Ludwig Center for Molecular Oncology, Cambridge, MA 02139, USA

Running Title
PGE2 and the MSC-derived cancer stem cell niche

Keywords
prostaglandin E2, mesenchymal stem cell, cancer stem cell, epithelial-mesenchymal transition, Interleukin-1

Financial support: Breast Cancer Research Foundation (R.A.W.), Susan G. Komen for the Cure (H.L.), National Institutes of Health (R.A.W.: U54CA163109 and H.R.H: R01CA123055 and P50CA086306), and Ludwig Center for Molecular Oncology (R.A.W.).

Corresponding author: Robert A. Weinberg
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142
phone: 1-617-258-5159
fax: 1-617-258-5230
e-mail: weinberg@wi.mit.edu

Conflict of interest statement: No potential conflicts of interest were disclosed.

Words: 7811
Figures: 7
Abstract

Mesenchymal cells of the tumor-associated stroma are critical determinants of carcinoma cell behavior. We focus here on interactions of carcinoma cells with mesenchymal stem cells (MSCs), which are recruited to the tumor stroma and, once present, are able to influence the phenotype of the carcinoma cells. We find that carcinoma cell-derived interleukin-1 (IL-1) induces prostaglandin E2 (PGE2) secretion by MSCs. The resulting PGE2 operates in an autocrine manner, cooperating with ongoing paracrine IL-1 signaling, to induce expression of a group of cytokines by the MSCs. The PGE2 and cytokines then proceed to act in a paracrine fashion on the carcinoma cells to induce activation of β-catenin signaling and formation of cancer stem cells. These observations indicate that MSCs and derived cell types create a cancer stem-cell niche to enable tumor progression via release of PGE2 and cytokines.
Significance

While prostaglandin E$_2$ has been implicated time and again in fostering tumorigenesis, its effects on carcinoma cells that contribute specifically to tumor formation are poorly understood. Here we show that tumor cells are able to elicit a strong induction of the COX2/mPGES1/PGE$_2$ axis in mesenchymal stem cells recruited to the tumor-associated stroma by releasing IL-1, which in turn elicits a mesenchymal/stem-cell-like phenotype in the carcinoma cells.
Introduction

Carcinoma cells recruit mesenchymal cells into the tumor-associated stroma; these mesenchymal cells then proceed to modify the stroma, helping to establish a tissue microenvironment that favors tumor progression. Paracrine signals emanating from the resulting tumor-associated stroma can subsequently modulate the behavior of the carcinoma cells (1).

Among the recruited stromal cells are bone marrow-derived mesenchymal stem cells (MSCs), which are known to exhibit multipotent differentiation potential (2). In the context of cancer pathogenesis, MSCs contribute to the formation of fibroblast and myofibroblast populations in the tumor-associated stroma (3, 4) and promote the growth, progression and metastasis of tumors (3, 5, 6). Precisely how MSCs influence tumor progression is, however, poorly understood.

Elevated cyclo-oxygenase-2 (COX2) mRNA and protein levels are found in many malignant tissues and are often associated with poor clinical outcome (7). The tumor-enhancing effects of COX2 are generally ascribed to its role in producing prostaglandin E2 (PGE2), which has pleiotropic effects on cell proliferation, survival, angiogenesis, motility and invasiveness (8). In addition to the neoplastic cells themselves, cells of the tumor-associated stroma contribute to elevated COX2 expression (9, 10). However, it has been unclear whether the PGE2 that promotes tumor progression derives from neoplastic cells, fibroblasts, macrophages, or some combination of these cell types.

Independent of these questions is the issue of heterogeneity of the neoplastic cells within carcinomas. Observations of a variety of human cancer types have revealed the existence of tumor-initiating cells (TICs), often called cancer stem cells (CSCs),
which coexist as minority populations within tumors together with a majority population of cancer cells that lack tumor-initiating ability (11). Passage by neoplastic epithelial cells through an epithelial-mesenchymal transition (EMT) allows these cells to approach the stem-cell state (12, 13). Moreover, EMT programs are known to be induced by heterotypic signals that epithelial cells receive from the microenvironment (14). However, the nature of these heterotypic signals and the identities of the stromal cells that release them remain poorly understood.

We demonstrate here that, in response to stimulation by carcinoma cells, MSCs express greatly elevated levels of PGE$_2$. The resulting PGE$_2$, together with cytokines also induced in the MSCs, contribute to entrance of nearby carcinoma cells into a stem-cell-like state.
Results

PGE₂ induction in MSCs following interaction with carcinoma cells

We initially studied the interactions in culture of LoVo and SW1116 human colorectal carcinoma cells with MSCs. Minimal PGE₂ accumulation was observed in pure LoVo, SW1116 or MSC cultures monitored over a 72 h period (Fig. 1Aa and Supplementary Fig. S1A). However, PGE₂ levels increased ~6.5 fold when the LoVo cells were cocultured with twice the number of MSCs for 48 h, and increased by ~60 fold after 72 h of coculture. Correspondingly, levels of the COX2 enzyme were also increased in the coculture (Fig. 1Ab). In contrast, there was no PGE₂ increase in SW1116/MSC cocultures. Of note, PGE₂ production was induced equally strongly in [LoVo][MSC] transwell cocultures, which only permitted their intercommunication via soluble factors (Supplementary Fig. S1B) and in MSCs treated with LoVo-conditioned medium (LoVoCM; Supplementary Fig. S1C and S1D). Hence, soluble factors secreted by LoVo cells were responsible for inducing PGE₂ production by MSCs.

Other work (in Supplemental Data, Section 1; Supplementary Figure S1E) demonstrated that the secretion of IL-1β and IL-1α by carcinoma cell populations was correlated with their respective abilities to elicit PGE₂ production in co-cultured MSCs. Thus, when MSCs were treated with recombinant IL-1β or IL-1α, the induced PGE₂ levels were similar to or higher than those induced by LoVoCM (Fig. 1Ba). Conversely, IL-1α- and IL-1β-neutralizing antibodies attenuated by 60% the production of LoVoCM-induced PGE₂ (Fig. 1Ba). In addition, shRNAs directed against IL-1α and IL-1β mRNAs expressed in LoVo cells decreased by 84% the ability of their CM to induce PGE₂ in MSCs (Fig. 1Bb) and recombinant IL-1ra, a natural antagonist of the IL-1 receptor,
attenuated by 73% the LoVoCM-induced PGE2 production by MSCs (Fig. 1Bc). IL-1α/β secreted by the carcinoma cells was largely responsible for the PGE2 production by MSCs, while IL-1ra could antagonize this induction.

Relationship of IL-1 production by carcinoma cells to their ability to induce PGE2

The levels of the IL-1α, IL-1β and IL-1ra mRNAs and secreted proteins were quantified in six human breast carcinoma cell lines and the SW1116 colorectal carcinoma cell line, in addition to the LoVo cells examined above. Cells of the LoVo, HCC1806, BT549, SUM149 and SUM159 lines expressed elevated levels of IL-1α and/or IL-1β, but relatively low levels of IL-1ra; conversely, MDA-MB-453, MDA-MB-231 and SW1116 cells secreted little or no detectable IL-1α/β and/or relatively high levels of IL-1ra (Supplementary Fig. S1F and Fig. 1Ca).

When cultured individually, the carcinoma cell lines expressed low or undetectable PGE2 levels (Fig. 1Cb). However, upon coculture with MSCs, the IL-1α/β-secreting carcinoma cells induced ~80-500-fold increases of COX2 and PGE2 production, while the carcinoma cells secreting low levels of IL-1α/β failed to stimulate COX2 or PGE2 formation (Supplementary Fig. S1G and Fig. 1Cb). In addition, IL-1α/-IL-1β-neutralizing antibodies and IL-1ra attenuated PGE2 production induced in MSCs by the conditioned media from the various IL-1-secreting carcinoma cells (Supplementary Fig. S1H). Hence, the ability to stimulate PGE2 in MSCs appeared to be a frequent but not universal property of breast and colon carcinoma cells and was directly correlated with their abilities to signal via secreted IL-1α/β. Because IL-1α and IL-1β were both
capable of PGE\textsubscript{2} induction, we use the term “IL-1” to refer to both IL-1\textsubscript{α} and IL-1\textsubscript{β} in the text that follows.

**Induction of cytokines in MSCs following their interaction with carcinoma cells**

In addition to PGE\textsubscript{2}, GRO-\textalpha, IL-6, IL-8 and RANTES in the culture media of LoVoMSC cocultures increased by 34, 10, 79 and 21 fold respectively following 120 h of coculture (Fig. 2A). In [LoVo][MSC] transwell cultures, where direct contact between the LoVo cells and MSCs was prevented, PGE\textsubscript{2}, GRO-\textalpha, IL-6 and IL-8 were induced to comparable levels; in contrast, RANTES expression was not elevated (Fig. 2A). Following direct coculture, RANTES production occurred far more rapidly than did the accumulation of the other cytokines or PGE\textsubscript{2} (Supplementary Fig. S2A).

We also found that GRO-\textalpha, IL-6 and IL-8, like PGE\textsubscript{2}, were induced by LoVoCM in MSCs (Supplementary Fig. S1B). To determine whether IL-1 was able, by itself, to induce concomitant production in MSCs of the three cytokines and PGE\textsubscript{2}, we assessed mRNAs levels in MSCs that had been treated for 48 h with vehicle or recombinant IL-1 (Fig. 2B). The resulting 10-fold and 4-fold increases in MSCs of COX2 and mPGES1 (a second PGE\textsubscript{2} biosynthetic enzyme) mRNAs, the increase of COX-2 protein, and the 10~100-fold decrease of 15-PGDH mRNA (encoding the PGE\textsubscript{2}-degrading enzyme) confirmed the key role of IL-1 in modulating the levels of enzymes governing PGE\textsubscript{2} production and accumulation in MSCs. Moreover, IL-1 treatment alone elicited substantial increases (36-440 fold) of IL-6, IL-8 and GRO-\textalpha mRNAs in MSCs. COX2, IL-6, IL-8 and GRO-\textalpha mRNA induction was detectable within 30 minutes of IL-1 exposure and reached a maximum at 1-2 h thereafter (Supplementary Fig. S2B). This key role of
IL-1 was further confirmed by knocking down IL1α/β mRNAs in LoVo cells, resulting in a 60-90% decrease in the induced levels of IL-6, IL-8 and GRO-α mRNAs (Supplementary Fig. S2C). Thus, IL-1 was both necessary and sufficient to induce PGE₂, IL-6, IL-8 and GRO-α production in MSCs.

We also confirmed that LoVoCM and IL-1 could induce comparable levels of PGE₂ (Supplementary Fig. S2D) and cytokine (Supplementary Fig. S2E) in other types of mesenchymal cells that may arise from the differentiation of MSCs (4), including human breast mesenchymal stem cells (bMSCs) isolated from a breast cancer patient, human colonic myofibroblasts (CCD-18co), and primary human mammary stromal fibroblasts.

**Autocrine PGE₂ cooperation with IL-1 paracrine signaling leading to PGE₂ and cytokine production by MSCs**

IL-8 and IL-6 are known to be induced in certain cells by PGE₂ (15). To determine whether PGE₂ played a role in the induction of these cytokines in MSCs, PGE₂ production by MSCs was blocked with indomethacin, which inhibits the COX1 and COX2 enzymes. In LoVo/MSC cocultures, GRO-α, IL-6 and IL-8 protein induction was reduced by 85-98% by indomethacin; moreover this induction could be partially rescued by providing PGE₂ to indomethacin-treated cocultures (Fig. 2C). While PGE₂ treatment alone could not induce GRO-α, IL-6 or IL-8 expression in LoVo cells or MSC cells, additional PGE₂ potentiated the cytokine induction in LoVo/MSC cocultures and in IL-1-treated MSCs (Fig. 2C and Supplementary Fig. S2F).
MSCs expressed two distinct PGE$_2$ cell-surface receptors, EP2 and EP4 (Supplementary Fig. S2G). To support the notion that MSC-derived PGE$_2$ acted in an autocrine fashion, the EP2 and EP4 receptor antagonists AH6809 and GW627368X were added to MSC cultures, along with either LoVoCM or IL-1. LoVoCM- and IL-1-induced IL-6, IL-8 and GRO-α mRNA was suppressed by 60-80% by these EP receptor antagonists (Fig. 2D). Figure 2E summarized our model that (i) COX2, mPGES1 and PGE$_2$ are initially induced in MSCs by IL-1 released by carcinoma cells and that (ii) the resulting PGE$_2$, acting in an autocrine manner on MSCs, then cooperates with ongoing IL-1 paracrine signaling to trigger IL-6, IL-8 and GRO-α production by MSCs (Fig. 2E).

**Effects of MSCs on carcinoma cell mesenchymal and invasive traits**

Before further analyzing the interactions between the carcinoma cells and MSCs, we confirmed that, as reported by others (5, 16), MSCs are indeed recruited to IL-1-secreting tumors *in vivo* (described in Supplemental Data, Section 2; Supplementary Fig. S3A-B). Having done so, we further investigated the influence of MSCs on carcinoma cell behavior, more specifically by analyzing the effects of MSC coculture on the expression by the tumor cells of markers of EMT, a cell-biological program that imparts motility, invasiveness, and self-renewal to carcinoma cells (14). After culturing, either alone or together with tdTomato-MSCs (5 days), LoVo and HCC1806 cells were isolated by FACS and analyzed for E-cadherin, vimentin, fibronectin and β-actin protein expression (Fig. 3A). E-cadherin, the key epithelial marker, was decreased by 98-100% in both LoVo and HCC1806 cells cocultured with MSCs. Conversely, vimentin and fibronectin proteins – both mesenchymal markers – were robustly induced in both
carcinoma cells (Fig. 3A). Moreover, expression of the Snail protein, an EMT-inducing transcription factor (EMT-TF), was increased 5-69 fold in the MSC:carcinoma cocultures (Fig. 3A).

We then determined whether PGE\textsubscript{2} and/or the cytokines produced by MSCs in LoVo/MSC cocultures could elicit an EMT-like response in LoVo cells. PGE\textsubscript{2} was able, on its own, to cause a decrease in E-cadherin protein in LoVo cells (Fig. 3B, ~70% decrease) but failed to elicit concomitant robust increases of mesenchymal markers, i.e., vimentin, and the Zeb1, Snail and Twist1 EMT-TFs (Fig. 3B).

In contrast to PGE\textsubscript{2}, IL-6 alone induced Zeb1 (7 fold), Snail (3 fold), and vimentin (3 fold) protein expression in LoVo cells, but was unable to decrease E-cadherin protein. However, treatment of LoVo cells with PGE\textsubscript{2} together with the four cytokines induced both a decrease of E-cadherin protein expression (~80%) and increases of vimentin (9 fold), Zeb1 (14 fold), Snail (13 fold) and Twist1 (10 fold) protein expression (Fig. 3B). Hence, activation of a more complete EMT program in the carcinoma cells required the concomitant activation of multiple signaling pathways, specifically those triggered in these cells by PGE\textsubscript{2} acting together with the indicated cytokines.

Significantly more carcinoma cells invaded in LoVo/MSC cultures than in cultures of LoVo cells alone (Fig. 3C). To examine whether PGE\textsubscript{2} played a critical role in the MSC-induced carcinoma cell invasiveness, LoVo/MSC cocultures were treated with NS398, a COX2 inhibitor; this treatment resulted in an 80% reduction of MSC-induced LoVo cell invasiveness (Fig. 3C). Greater than 60% of this inhibition could be reversed by adding PGE\textsubscript{2} to these cocultures.
Also, LoVo cell invasion was significantly reduced by antibodies that neutralize either IL-6, GRO-α or RANTES (Fig. 3D). Accordingly, the MSC-induced carcinoma cell invasiveness appeared to derive from a confluence of PGE₂, IL-6, GRO-α and RANTES signals impinging on the LoVo cells.

We also examined possible effects of MSCs on carcinoma cell invasion in vivo. The carcinoma cells injected on their own formed reasonably well-encapsulated tumors (Fig. 3E, a, b, c). In contrast, the carcinoma cells co-injected with MSCs formed extensive invasive fronts that extended into adjacent muscle layers (Fig. 3E, d, e, f). In addition, we observed the intravasation of carcinoma cells into nearby microvessels (Fig. 3E, insert). To summarize, these data indicated that MSCs facilitated LoVo cell invasion both in vitro and in vivo.

**Effects of MSCs on tumor initiation by carcinoma cells**

Since transformed epithelial cells that have undergone EMT contain larger subpopulations of TICs (12, 13, 17), we determined whether EMT induction of carcinoma cells by MSCs was similarly accompanied by an increase in tumor-initiating ability. When populations of $5 \times 10^4$ IL-1-secreting carcinoma cells were co-injected with $2 \times 10^5$ MSCs, their ability to give rise to palpable tumors was measurably increased (1/6 to 6/6 for LoVo, 1/6 to 6/6 for HCC1806, 0/6 to 5/6 for SUM159 and 1/6 to 5/6 for SUM149, Fig. 3F). In contrast, tumor initiation by $5 \times 10^4$ MDA-MB-231 or MDA-MB-453 cells, neither of which secrete IL-1, was not increased by co-injection with $2 \times 10^5$ MSCs.
We quantified these interactions more precisely by implanting limiting dilutions of LoVo cells at four dosages, together with $5 \times 10^5$ admixed MSCs. The presence of admixed MSCs increased the tumor-initiating frequencies of $5 \times 10^5$, $5 \times 10^4$ and $5 \times 10^3$ implanted LoVo cells from 4/6, 1/6 and 0/6 to 6/6, 6/6 and 6/6. (Fig. 3G). As judged by the ELDA (Extreme limiting dilution analysis) (18), the frequency of TICs in cultured LoVo cells was $9 \times 10^{-7}$ - $6 \times 10^{-5}$; in the presence of admixed MSCs this frequency increased to $1 \times 10^{-3}$ - $1 \times 10^{-2}$ (Fig. 3H).

**MSC-induced increases in ALDH$^{\text{high}}$ CSC-enriched population and tumor initiation**

CSCs, which have some characteristics associated with normal stem cells, are cells defined operationally by their tumor-initiating ability (19). We validated the use of aldehyde dehydrogenase as a marker of tumor-initiating cells and thus CSCs (20, 21) (described in Supplemental Data, Section 3; Supplementary Fig. S4A-C and S5A-B). We observed that a 5-day coculture of LoVo or HCC1806 cells with MSCs resulted in ~7-fold and ~20-fold increases, respectively, in ALDH1 protein levels in the carcinoma cells (Fig. 4A and Supplementary Fig. S5C). To extend this observation, we cultured an unfractionated LoVo cell population or already-sorted ALDH$^{\text{high}}$ or ALDH$^{\text{low}}$ LoVo cell subpopulations (Supplementary Fig. S4Ba), either alone or in the presence of a two-fold excess of tdTomato-labeled MSCs, for 5 days. All three LoVo cell populations, when cocultured with MSCs, developed larger subpopulations of ALDH$^{\text{high}}$ cells (59%, 38% and 18%) than when cultured alone (38%, 20% and 7%), i.e., 1.6- to 2.6-fold increases in ALDH$^{\text{high}}$ cells (Fig. 4Ba).
We also used FACS to remove the tdTomato-MSCs from LoVoMSC cocultures, then further propagated the LoVo cells for 5 days in the absence of MSCs. We found that the levels of the ALDH$^{\text{high}}$ LoVo cell subpopulations that had previously been increased by coculture with MSCs reverted to levels comparable to those observed in LoVo cells that had never experienced MSC coculture (Fig. 4Bb). Our data indicated that maintenance of elevated numbers of ALDH$^{\text{high}}$ LoVo cells depended on continuous interactions of the LoVo cells with MSCs.

Use of the ALDH marker as the sole stem-cell marker is likely to have led to an underestimate in the increase of the number of CSCs, since ALDH$^{\text{high}}$ cells are a CSC-enriched population rather than being a pure CSC population. In order to refine the markers used to identify CSCs, we determined that a LoVo subpopulation more enriched for CSCs could be identified by concomitant use of the ALDH$^{\text{high}}$ and CD133$^+$ markers, which have been used to define CSCs in various cancer cell populations (22-25) (described in Section 3, Supplemental Data; Supplementary Fig. S6A-C). Indeed, in the LoVo cells cocultured for five days with MSCs, the ALDH$^{\text{high}}$/CD133$^+$ LoVo cells were increased from 1.4% to 16.4% of the overall cell population, i.e., a 11.7-fold increase (Supplementary Fig. S6C).

We also determined whether the MSC-induced increase of ALDH$^{\text{high}}$ LoVo cells observed in culture was accompanied by an increase of TICs in LoVo cells. Limiting dilutions of sorted ALDH$^{\text{high}}$ and ALDH$^{\text{low}}$ LoVo cells were injected subcutaneously into SCID mice, either alone or together with MSCs (Fig. 4Ca). As calculated using ELDA, the TIC frequency of ALDH$^{\text{high}}$ LoVo cells injected on their own was $4 \times 10^{-5} - 3 \times 10^{-4}$, while that of ALDH$^{\text{high}}$ LoVo coinjected with MSCs was $2 \times 10^{-3} - 1$ (Fig. 4Cb). For
ALDH\textsuperscript{low} LoVo cells injected alone, the TIC frequency was $7 \times 10^{-7} - 5 \times 10^{-6}$; co-injection with MSCs increased this frequency to $3 \times 10^{-4} - 2 \times 10^{-3}$ (Fig. 4Cb). TIC frequencies of both ALDH\textsuperscript{high} and ALDH\textsuperscript{low} LoVo cells were increased by several orders-of-magnitude when co-injected with MSCs.

The continued presence of MSCs in the implanted cell populations complicates interpretation of the direct effects of MSC on the tumor initiation of carcinoma cells, since the MSCs might affect tumor initiation by a number of different mechanisms. To address this issue, LoVo cells or HCC1806 cells were isolated by FACS from 5-day carcinoma cell/tdTomato-MSC cocultures and were then immediately injected subcutaneously into SCID mice, in parallel with LoVo cells previously cultured alone, in order to determine the effect on the tumor initiation of the cell culture interactions (Fig. 4D and Supplementary Fig. S7A). Accordingly, TIC frequencies of LoVo cells were increased by one order-of-magnitude following 5-day co-culture with MSCs in vitro (Supplementary Fig. S7B). An increase of tumor initiation by prior co-culture with MSCs was also observed on HCC1806 cells (Supplementary Fig. S7C).

**Influence of PGE\textsubscript{2} signaling on the ALDH\textsuperscript{high} CSC state**

To understand more precisely how the signals exchanged between carcinoma cells and MSCs led to increases in ALDH\textsuperscript{high} CSCs, we first ascertained whether PGE\textsubscript{2} and/or cytokines produced by MSCs in LoVo/MSC cocultures could elicit ALDH1 expression. Only PGE\textsubscript{2} was able, on its own, to elicit an increase in ALDH1 expression in LoVo cells (Fig. 5A). Moreover, when PGE\textsubscript{2} was combined with the four cytokines there was no further increase in ALDH1 expression.
EP4 is the only PGE\textsubscript{2} receptor highly expressed by LoVo cells (Supplementary Fig. S2G). To elucidate in more depth the effects of PGE\textsubscript{2} on LoVo cells, we treated these cells with vehicle or PGE\textsubscript{2} for 5 days. The vehicle-treated cultures contained 10.3\% ALDH\textsuperscript{high} LoVo cells, while the LoVo cells treated with PGE\textsubscript{2} contained ~25\% ALDH\textsuperscript{high} LoVo cells (Fig. 5B). We added GW627368X (the EP4 receptor antagonist) to LoVo cells to determine whether the basal, unperturbed levels of ALDH\textsuperscript{high} cells depended on ongoing PGE\textsubscript{2} autocrine signaling; this treatment reduced by ~60\% the basal level of ALDH\textsuperscript{high} LoVo cells (Fig. 5B). These data suggested that within LoVo cells, subpopulations of cells are maintained in an ALDH\textsuperscript{high} state in part through ongoing, low-level autocrine PGE\textsubscript{2} signaling. Moreover, this signaling and associated entrance into the ALDH\textsuperscript{high} state could be enhanced by exogenously supplied PGE\textsubscript{2}.

The observed increase in ALDH1 expression induced by PGE\textsubscript{2} was not confined to LoVo cells. PGE\textsubscript{2} treatment induced elevated ALDH1 expression (2.9 - 12.9 fold) in LoVo, SUM149, SUM159 and BT549 cells (Fig. 5C), all of which were previously found to elicit increased PGE\textsubscript{2} production from cocultured MSCs.

The LoVo cells that had been treated \textit{ex vivo} with vehicle or PGE\textsubscript{2} for 5 days were implanted subcutaneously in SCID mice. Tumors derived from control LoVo cells occurred in 3 of 16 injected hosts, while the corresponding PGE\textsubscript{2}-treated cells formed tumors in 18 of 24 hosts (Fig. 5D). Hence, a substantial increase in ALDH\textsuperscript{high} cells and TICs could be achieved by PGE\textsubscript{2} treatment of LoVo cells \textit{ex vivo}. Moreover, treating LoVo cells with the cocktail of cytokines (IL-6, IL-8, Gro-\textalpha and RANTES) in addition to PGE\textsubscript{2} did not significantly increase the tumor initiation beyond that observed for PGE\textsubscript{2} treatment alone (Supplementary Fig. S8). In addition to its effects on TICs, PGE\textsubscript{2} is
likely to contribute to the maintenance of CSCs \textit{in vivo} by increasing tumor angiogenesis (Supplementary Fig. S9, discussed in Supplemental Data, section 4).

**Role of PGE$_2$ signaling in the MSC-induced ALDH$^{\text{high}}$ CSC-enriched population and tumor initiation.**

To confirm that the above-described role of PGE$_2$ could explain the ability of MSCs to induce CSC formation, we inhibited PGE$_2$ synthesis with NS398, or PGE$_2$ signaling with GW627368X, in cocultures of LoVo cells and tdTomato-MSCs. Blocking PGE$_2$ signaling by either route prevented most of the increases in ALDH$^{\text{high}}$ LoVo CSCs by MSCs (described in Section 5, Supplemental Data; Supplementary Fig. S10). LoVo cells that had been cocultured under the various conditions with MSCs for 5 days were sorted by FACS to eliminate tdTomato-MSCs and were then injected subcutaneously into SCID mice. The increase in TIC frequencies resulting from a 5-day coculture with MSCs (from 4/20 to 14/19) was prevented by introducing either NS398 or GW627368X into the cocultures (from 14/19 to 3/17 or 1/12, respectively, Fig. 5E). Adding PGE$_2$ to the cocultures along with NS398 restored the tumor-initiating frequency from 3/17 to 7/8.

To validate the role of COX2 in these properties, we knocked down COX2 in MSCs. The ability of the resulting MSCshcox-2 cells to produce PGE$_2$ in response to LoVoCM was reduced by 90\% (Fig. 5Fa). The tumor-initiating frequency of $5 \times 10^4$ LoVo cells was increased from 1/12 to 10/12 by co-injection with MSCs expressing a control, scrambled shRNA (MSCshsc cells; Fig. 5Fb). In contrast, in mice co-injected with MSCshcox2 cells, the tumor-initiating frequency of LoVo cells was increased from 1/12
to only 3/12, supporting the notion that COX2-dependent PGE2 induced in MSCs was required for the observed robust increases of LoVo TICs.

**PGE2 induces β-catenin nuclear localization and transactivation**

The β-catenin signaling pathway has been implicated in maintaining stem cell and CSC homeostasis in most epithelial tissues (26, 27). Relevant here is the finding that PGE2 treatment leads to Akt activation; activated Akt subsequently stimulates β-catenin signaling in several ways (28, 29). Accordingly, we examined activation of Akt/GSK-3/β-catenin signaling axis in LoVo cells treated with vehicle, PGE2, GW627368X, or GW627368X + PGE2. We found that PGE2 treatment led to a 12-fold increase in Akt phosphorylation at Thr473 (Fig. 6A), which indicates functional Akt activation (30). Conversely, inhibiting PGE2 signaling with GW627368X in PGE2-treated LoVo cells blocked 50% of the PGE2-induced Akt phosphorylation (Fig. 6A). Moreover, β-catenin activity is positively affected by Akt-mediated phosphorylation of its Ser552 residue (31, 32). PGE2 treatment of LoVo cells, which caused a 12-fold increase of Akt phosphorylation, also increased β-catenin phosphorylation at Ser552 (11 fold), an increase that was blocked entirely by GW627368X treatment (Fig. 6A).

Akt also enhances β-catenin by phosphorylating and thereby inactivating glycogen synthase kinase-3 (GSK3); this prevents inactivation of β-catenin by unphosphorylated GSK3, since Ser21-unphosphorylated GSK-3α and Ser9-unphosphorylated GSK-3β phosphorylate β-catenin at its Ser33/Ser37/Thr41 residues, leading to its degradation (33, 34). PGE2 strongly increased the phosphorylation of GSK-3α at Ser21 (56 fold above basal level, Fig. 6A). Although Ser9 of GSK-3 was
already phosphorylated prior to PGE\textsubscript{2} treatment, this basal level of GSK-3β Ser9 phosphorylation was reduced (70\%) by adding GW627368X (Fig. 6A), presumably by blocking basal autocrine PGE\textsubscript{2} signaling. Inhibition of PGE\textsubscript{2} signaling by GW627368X prevented the inactivating phosphorylation of GSK-3α and GSK-3β and, conversely, increased phosphorylation of β-catenin at Ser33/Ser37/Thr41 residues 15 fold that lead to its degradation(Fig. 6A). These data indicated that inhibition of PGE\textsubscript{2} signaling leads to β-catenin phosphorylation, a prelude to its proteasomal degradation.

A strong inhibition of β-catenin signaling is also achieved by E-cadherin, which recruits β-catenin to adherens junctions associated with the plasma membrane, thereby preventing its nuclear localization and its actions in promoting transcription (35). PGE\textsubscript{2} decreased the E-cadherin and ZO-1 protein located at the cell junctions (Fig. 6B and 6C). Correspondingly, in PGE\textsubscript{2}-treated LoVo cells β-catenin was found in cell nuclei, rather than being sequestered by E-cadherin in adherens junctions, (Fig. 6B and 6C). PGE\textsubscript{2} caused a 5.3-fold increase of β-catenin in the nuclear fraction; this increase was blocked by adding the EP4 antagonist during PGE\textsubscript{2} treatment (Fig. 6D). We also found, by analyzing expression in LoVo carcinoma cells of a number of β-catenin/TCF-regulated genes, that PGE\textsubscript{2}–induced nuclear β-catenin was functionally active (Fig. 6E).

**PGE\textsubscript{2}-induced effects on ALDH\textsuperscript{high} cancer cells are mediated by β-catenin signaling**

PGE\textsubscript{2} induces Akt phosphorylation in carcinoma cells in a phosphatidylinositol 3-kinase (PI3K)-dependent manner (28). To determine if the activation of the Akt/GSK-3/β-catenin signaling axis was required for PGE\textsubscript{2}-induced ALDH\textsuperscript{high} LoVo CSCs, we
treated ALDH\textsuperscript{high} LoVo cells with vehicle, PGE\textsubscript{2}, GW627368X, LY294002 (a PI3K inhibitor), FH353 (a β-catenin/TCF inhibitor), or cardamonin (a β-catenin inhibitor) for 5 days at concentrations that did not cause significant cell death.

LY294002 functioned as efficiently as the EP4 antagonist by completely blocking the exogenous PGE\textsubscript{2}-induced increase of ALDH\textsuperscript{high} LoVo cells and by decreasing the endogenous PGE\textsubscript{2}-maintained basal ALDH\textsuperscript{high} LoVo cells (Fig. 6F, a and d). Although the two β-catenin inhibitors, FH353 and cardamonin, blocked the PGE\textsubscript{2}-induced increase of ALDH\textsuperscript{high} LoVo cells (Fig. 6Fb and 6Fc), these inhibitors did not function as effectively as the EP4 antagonist or the PI3K inhibitor. PGE\textsubscript{2}/EP4 signaling, acting through the Akt/GSK-3/β-catenin signaling axis (28), contributes to induction of the ALDH\textsuperscript{high} LoVo cell phenotype.

**Contribution of MSCs in tumor stroma to the stem-cell niche of ALDH\textsuperscript{high} CSCs**

PGE\textsubscript{2} is metabolically unstable and is thought to act within tissues over short distances, doing so in both an autocrine and a paracrine manner. Wishing to pursue this notion further, we examined whether ALDH\textsuperscript{high} CSCs were located near MSCs (or their mesenchymal derivatives) in tumors that arose following the coinjection of these two cell types. ALDH\textsuperscript{high} LoVo cells (Fig. 7Aa, red signal) were often surrounded by tdTomato-labeled MSCs (Fig. 7Aa, green signal) or their derivatives in tissue sections of LoVo/MSC xenografts; in addition, many of these mesenchymal cells expressed COX2 (Fig.7Aa, cyan signal). Moreover, the mesenchymal cells associated with the ALDH\textsuperscript{high} tumor cells expressed FSP, the fibroblast marker (Fig 7Ab, red signal; discussed in Supplemental Data, section 6; Supplementary Fig. S11), indicating that the MSC-
derived fibroblasts rather than their MSC precursors were largely responsible for forming the stromal microenvironment of these ALDH\textsuperscript{high} cells. The conclusion that PGE\textsubscript{2} induces the formation of ALDH\textsuperscript{high} CSCs was further supported by human colorectal adenocarcinoma studies in which we found the juxtaposition within tumors of such CSCs with stroma expressing COX2, the likely source of PGE\textsubscript{2} production (discussed in Supplemental Data, section 7; Supplementary Fig. S12A-B). These observations lead us to propose that MSCs (or their differentiated derivatives) create a niche within tumors, leading to induction and/or maintenance of CSC subpopulations.

**Correlation of COX2 expression with CSC properties and a more aggressive tumor phenotype**

To determine whether elevated IL-1 production correlates with COX2/PGE\textsubscript{2} expression in human primary carcinomas, we compared the normalized IL-1\textsubscript{α}, IL-1\textsubscript{β} and COX2 mRNA levels across 19 human normal colon and 123 human colon carcinoma samples and across 178 human invasive breast carcinoma samples [Cancer Genome Atlas analyzed by Oncomine™]. IL-1\textsubscript{α} and IL-1\textsubscript{β} were expressed at significantly higher levels (9.6 fold and 4.7 fold in colon carcinoma and 2.1 fold and 2.1 fold in breast carcinoma) in aggressive subtypes of samples --- colon mucinous carcinoma and Triple-negative breast carcinoma (TNBC) respectively (Fig. 7B). Moreover, the COX2 mRNA levels were correlated with the IL-1\textsubscript{α} and IL-1\textsubscript{β} mRNA levels; COX2 mRNA was elevated 5.4 fold and 5.3 fold in colon mucinous carcinoma and TNBC when compared to normal colon samples and other breast cancers (Fig. 7B). These correlations suggested that the signaling mechanisms described above (Fig. 7C),
involving IL-1 activated expression of COX2/PGE$_2$, may be relevant to understanding the pathogenesis of colon mucinous carcinomas and TNBCs.
Discussion

Elevated IL-1 expression has been correlated with increased malignant progression and more aggressive phenotypes in many types of cancer (36). However, the mechanism(s) underlying this correlation have been unclear. We describe here a bidirectional, reciprocal interaction between carcinoma cells and the MSCs (Fig. 7C). The signaling is initiated through the release of IL-1 by carcinoma cells. We present evidence that appears to explain this connection between IL-1 production and increased tumor aggressiveness in many, and perhaps all IL-1-secreting carcinomas.

IL-1 secreted by carcinoma cells induces COX2 and mPGES1 expression in MSCs. The two enzymes collaborate in MSCs to generate PGE2 levels, which can increase by 80 to 500 fold (Fig. 1Cb). Of note, we show these responses operate equally well in MSCs and in their more differentiated descendants (Supplementary Fig. S2D and S2E). We note that others recently reported that IL-1 secreted by head-and-neck squamous cell carcinoma cells induce PGE2 from fibroblasts (37). Consequently, fibroblasts and myofibroblasts, both of which accumulate in large numbers in the stroma, may also represent sources of the PGE2 and the subsequently produced cytokines described here.

Importantly, while COX2 is highly expressed in both neoplastic and stromal cells in tumors, not all COX2-expressing cells can produce PGE2. Thus, despite large variations in COX2 expression, the colorectal carcinoma cell lines that we examined produced only about 10-40 pg/ml of PGE2 (Supplementary Fig. S1A). These levels are dwarfed by the 15,000-40,000 pg/ml of produced by the IL-1-stimulated MSCs studied here (Fig. 1Cb). This failure by COX2-expressing carcinoma cells to produce significant
levels of PGE₂ may be due to the absence in many carcinoma cells of significant levels of mPGES1 expression (Supplementary Fig. S1A and S1D). Hence, COX2 expression, on its own, is unlikely to provide an accurate indication of PGE₂ production by carcinomas.

MSC-produced PGE₂ acts in two ways within such tumors – in an autocrine fashion on the MSCs that produced it and in a paracrine fashion on the nearby IL-1-releasing carcinoma cells. The MSC autocrine signaling elicits a second wave of signaling responses: In collaboration with ongoing paracrine IL-1 signaling from carcinoma cells, the autocrine PGE₂ induces IL-6, IL-8, GRO-α and RANTES cytokines in the MSCs. Together, these MSC-derived molecules induce a third wave of responses that profoundly alter the carcinoma cells that initiated this signaling cascade (Fig. 2E and 7C).

The changes induced in carcinoma cells by the confluence of PGE₂ and cytokine signals are all components of the complex cell-biological program termed the EMT. While this program has been increasingly implicated in the acquisition of phenotypes associated with high-grade malignancy (14), major questions concerning the EMT have remained unanswered. Among them are the paracrine signals, ostensibly of stromal origin, that trigger the EMT in carcinoma cells. Here we present a scenario that explains how the EMT can be induced in carcinoma cells by a reactive stroma.

The present work also addresses another longstanding puzzle concerning the EMT: Is it usually activated as a single, coherent program or, alternatively, are distinct components of this program activated separately, each by a distinct set of heterotypic signals? Our observations indicate that the latter scenario is more likely. For example,
PGE2 caused a decrease of E-cadherin expression in carcinoma cells, while cytokines were required to induce the vimentin and ZEB1 expression that is usually depicted as intrinsic components of EMT program (Fig. 3B). Such responses suggest the possibility that, during the course of spontaneous tumor progression, some carcinoma cells may receive only a subset of these signals and accordingly only activate portions of the EMT program, while others receiving the complete suite of heterotypic signaling molecules may pass through an entire EMT program.

Research by ourselves and others has connected EMT with entrance into a stem-cell like state, both in normal and neoplastic epithelial cells (12, 13, 17). These findings are also echoed by the present work, in which we observe a concomitant entrance into the mesenchymal and stem-cell states in response to MSC-derived heterotypic signals. PGE2, which activated portions of the EMT program, was able to increase both the number of CSCs and the frequency of tumor initiation (Fig. 5A-5D). Our findings here further clarify the connection of EMT with entrance into a stem-cell like state by showing that the partial EMT induced by PGE2, which represses cell-cell junctions without inducing mesenchymal traits, suffices to increase CSCs. The observation of MSC-induced increases in CSCs is consistent with the recent finding of prostaglandin-induced increases in the number of CD44+ tumor cells (38, 39). The unique contribution of PGE2 is underscored by the observation that other MSC-derived cytokines, when combined with PGE2, had only marginal effects on further increasing the TIC frequency (Supplementary Fig. S8).

In earlier work (27), we documented an alternative means of activating the EMT program that involves canonical and non-canonical Wnts together with TGFβ. Those
findings echoed the present observations, since both studies demonstrated that multiple distinct heterotypic signals, acting in concert, are required to activate an EMT in carcinoma cells. These earlier findings left open the possibility that other EMT-inducing signals beyond those documented at the time may converge on the Wnt and TGFβ signaling pathways to activate EMT programs. We note here that PGE₂-activated signals do, indeed, converge on one of these signaling cascades by activating β-catenin signaling, the same pathway that represents the main signaling channel lying downstream of canonical Wnt signaling.

In tumors that arise from IL-1-producing carcinoma cells, we find that this interleukin plays a critical role in the tumor cell-induced COX2/mPGES1/PGDH/PGE₂ response in MSCs that is required for tumor progression. IL-1 blockage has been used in thousands of patients to control infection and inflammatory disease and has a remarkable safety record (40). Based on our findings and the existing clinical use of IL-1 inhibitors, IL-1 inhibition may present a promising alternative to COX2 inhibitors for cancer therapy. In addition, limited therapeutic options are currently available for TNBCs, which produce higher levels of IL-1 (Fig. 7B), because they are unresponsive to standard receptor-mediated treatments. Accordingly, our findings suggest a possible option for treating these aggressive subtypes of breast and colon cancer.
Materials and Methods

Cell Culture

Human carcinoma cell lines HCC1806, BT549, MDA-MB-231, -453, SW1116 and LoVo were obtained from ATCC and human bone-marrow derived MSC (Sciencell) were obtained from Sciencell. SUM149 and SUM159 cells were provided by SP Ethier (Wayne State University). The human carcinoma cell lines SUM149, SUM159, BT549, MDA-MB-231, -453, SW1116 and LoVo were authenticated by microarray analysis. HCC1806 and MSC were not passaged more than 6 months after receipt.

Animal experiments

All research involving animals complied with protocols approved by the MIT Committee on Animal Care. In experiments evaluating tumor initiation and growth, the tumors were isolated and weighed at the end of each experiment. To measure TIC frequency, serial dilutions of cancer cell suspensions were injected subcutaneously into nude mice. TIC frequencies of the samples were determined using the ELDA webtool (18).

PGE₂ and cytokine assays

The concentrations of PGE₂ and cytokines were determined by ELISA as described in the manufacturers’ protocols. PGE₂ levels were measured using a PGE₂ EIA assay kit (GE healthcare). Human cytokine levels were measured using Quantikine kits (R&D systems).
Invasion assay

Cell invation was evaluated by using BD Matrigel™ Invasion Chambers, 8.0 μm (BD biosciences). The cells that migrated through the membrane during the incubation period were counted in five randomly selected regions.

See Supplemental Materials and Methods  for more information.
Acknowledgments

We thank members of the Weinberg lab (Wai Leong Tam, Michael Hwang) and the Herschman lab (Tomo-o Ishikawa, Art Catapang) for discussion and technical support; the Whitehead Flow Cytometry Core for technical support; Sarah Dry and the UCLA TPCL for providing colon adenocarcinoma samples. This research was supported by Breast Cancer Research Foundation (R.A.W.), Susan G. Komen for the Cure (H.L.), National Institutes of Health (R.A.W.: U54CA163109 and H.R.H: R01CA123055 and P50CA086306), and Ludwig Center for Molecular Oncology (R.A.W.).
References


Figure Legends

Fig. 1. Carcinoma cell secreted IL-1 induces PGE$_2$ production in MSCs. (A) PGE$_2$ (Panel a) and COX-2 (Panel b) were measured in the indicated CM or cultures. PGE$_2$ data are means ± SE, n = 3. ***p < 0.005 (vs that in LoVo medium). LoVo+MSC; LoVo lysate and MSC lysate mixed in equal amounts; LoVoMSC, lysate of LoVoMSC coculture. The same nomenclature applies to the SW1116 cells. (B) Panel (a) MSCs were treated with LoVoCM, LoVoCM with neutralizing antibodies (500 ng/ml), or IL-1 only. Panel (b) MSCs were cocultured with LoVo cells expressing shRNAs against IL1$_\alpha$+IL1$_\beta$ (LoVoshIL1$_\alpha$β-1, LoVoshIL1$_\alpha$β-2), IL1$_\beta$ (LoVoshIL1$_\beta$-1, LoVoshIL1$_\beta$-2), or a scrambled sequence (LoVoshsc). Panel (c) MSCs were treated with DME, LoVoCM, or LoVoCM+IL-1ra. After incubation, media were collected and assayed for PGE$_2$. Data are means ± SE, n = 3. (C) Panel (a) IL-1$_\alpha$, IL-1$_\beta$, and IL-1ra protein levels in CM of the carcinoma cells. Data are means ± SE, n = 3. Panel (b) PGE$_2$ levels in carcinoma cells, MSCs (M), and co-cultures of the carcinoma cells with MSCs. Data are means ± SE, n = 3. ***p < 0.005 (vs that in MSC culture).

Fig. 2. IL-1 and PGE$_2$ mediate GRO-α, IL-6 and IL-8, but not RANTES induction in carcinoma cell-MSC coculture. (A) Levels of PGE$_2$ and the cytokines were measured in CM from the cultures. Data are means ± SE, n = 3. **p < 0.01, ***p < 0.005 (vs that in MSC culture). (B) mRNA levels of the enzymes governing PGE$_2$ production and the cytokines (upper panel) and COX2 protein levels (lower panel) in MSCs treated with IL-1 as indicated. Data are means ± SE, n = 3. *p < 0.05, **p < 0.01, ***p < 0.005 (vs
control). (C) Cytokine levels in CM from MSCs, LoVo cells and LoVoMSC cocultures, in the presence of indomethacin (indo; 100 μM), PGE₂ (100 nM), or Indo + PGE₂. Data are means ± SE, n = 3. (D) IL-6, IL-8 and Gro-α mRNA induction in MSCs either by LoVoCM or by IL-1 in the presence of EP2 and EP4 antagonists (AH6809 15 μM + GW627368X 20 μM). mRNA levels are set as 0% for vehicle-treated MSCs and 100% for LoVoCM-treated or IL-1-treated MSCs. Data are means ± SE, n = 3. *p < 0.05, **p < 0.01 (vs MSC treated with LoVoCM or IL-1 without inhibitors). (E) The proposed interactions for PGE₂ and cytokine induction from MSCs. AA: arachidonic acid.

**Fig. 3.** MSCs elict EMT, invasion of carcinoma cells, and increased tumor initiation of xenografts. (A) E-cadherin (E-cad), vimentin (VIM), fibronectin, Snail, and β-actin protein expression in carcinoma cells cultured either alone or with MSCs. The numbers indicate relative protein levels. (B) EMT markers and EMT-TFs were measured in LoVo cells treated with vehicle, PGE₂ (100 nM) or the cytokines (100 ng/ml IL-6, 100 ng/ml IL-8, 100 ng/ml GRO-α, and/or 10 ng/ml RANTES) as indicated for 6 days. (C) (Left panel) LoVo-tdTomato cells were cultured either alone or with MSCs in the upper wells of Boyden chambers. The presence or absence of NS-398 (50 μM) or NS-398 + PGE₂ (100 nM) is indicated for each panel. The images show the LoVo-tdTomato cells that migrated through the Matrigel-coated membranes in 72 h. Scale bar = 100 μm. (Right panel), Data are means ± SE, n = 3. (D) LoVo cell migration in LoVoMSC coculture treated with cytokine neutralizing antibodies as indicated. Data are means ± SE, n = 5. (E) MSCs increase invasion of LoVo tumors. LoVo (5 × 10⁵ cells/injection) were injected subcutaneously into SCID mice either alone (a, b, c) or with
MSCs (5 × 10^5 cell/injection, d, e, f). After 8 weeks, tumors of comparable size were isolated. H&E staining was performed on the tumor sections. Scale bar = 100 μm. (F and G) Weights of tumors derived from (F) carcinoma cells (5 × 10^4 cells/injection) and (G) LoVo cells injected into SCID mice, either alone or with MSCs. Filled circles indicate individual tumor weights; Open circles indicate no tumor grew at the site of injection. Bars are means ± SE. (H) The ranges of the estimated tumor-initiating frequencies in panel G evaluated by ELDA (with 95% confidence).

Fig. 4. MSC-induced increase in tumor initiation is reflected in an increase in ALDH\textsuperscript{high} CSC-enriched populations. (A) ALDH1 protein expression in LoVo cells cultured either alone or with MSCs. The numbers indicate relative protein levels. (B) Unsorted (whole), ALDH\textsuperscript{high} and ALDH\textsuperscript{low} LoVo cells were cultured either alone or with dTtomato-MSCs. After 5 days, ALDH activity of LoVo cells was analyzed by flow cytometry (panel a) and dTtomato-MSCs were removed from the cultures by flow sorting. After removing MSCs, the LoVo cells were cultured alone for another five days. The ALDH activities were again analyzed by flow cytometry (panel b). The percentages indicate the percentage of ALDH\textsuperscript{high} LoVo cells; i.e., percent of LoVo cells with ALDH activity beyond the indicated thresholds. (C) a: Weights of tumors derived from ALDH\textsuperscript{high} or ALDH\textsuperscript{low} LoVo cells injected into SCID mice, either alone or with MSCs. Solid-filled and hash-filled circles indicate individual tumor weights; open circles indicate no tumor grew at the site of injection. Red circles: injection of ALDH\textsuperscript{high} LoVo cells. Blue circles: injection of ALDH\textsuperscript{low} LoVo cells. Hash-filled circles: injection of LoVo cells, Solid-filled circles: injection of LoVo cells and MSCs. Bars are means ± SE, b: The ranges of the
estimated tumor-initiating frequencies evaluated by ELDA. (D) LoVo cells cultured with tdTomato-MSCs have increased numbers of TICs. Cells were cultured as in panel B. After isolating LoVo cells by sorting, cells (5 × 10⁴ cells/injection) were injected into mice. After 6 weeks, the tumors were isolated and weighted. Filled circles indicate individual tumor weights; Open circles indicate no tumor grew at the site of injection. Bars are means ± SE.

**Fig. 5. COX2-PGE₂ signaling is required for MSC-induced increase in ALDH\textsuperscript{high} CSC-enriched population and tumor initiation.** (A) ALDH1 protein expression in LoVo cells treated as indicated for 5 days. (B) ALDH activities of LoVo cells treated with vehicle, PGE₂ (100 nM) or GW627368X (20 μM) was analyzed by flow cytometry. The percentages indicate the percentage of ALDH\textsuperscript{high} LoVo cells; i.e., LoVo cells with ALDH activity beyond the indicated thresholds. The gray line at the right side of the plot indicates the threshold of the high ALDH activity. (C) ALDH1 protein levels in various carcinoma cells treated with vehicle or PGE₂. The numbers indicate relative protein levels. (D) PGE₂ increases LoVo TICs. LoVo cells pre-treated with vehicle or PGE₂ (100 nM) were injected into SCID mice (5 × 10⁴ cells/injection). After 6 weeks, tumors were isolated and weighted. Bars are means ± SE. (E) LoVo cells were cultured with tdTomato-MSCs, PGE₂, NS398 or GW627368X, as indicated. After 5 days, the LoVo cells were isolated by cell sorting and injected into SCID mice (5 × 10⁴ cells/injection). After 7 weeks, the tumors were isolated and weighted. Filled circles indicate individual tumor weights; Open circles indicate no tumor grew at the site of injection. Bars are means ± SE. (F) Panel (a), levels of PGE₂ secreted by LoVoCM-treated MSCshsc and MSCshcox2. Data are means ± SE, n = 3. Panel (b), Weights of tumors derived from
LoVo cells (5 \times 10^4 \text{ cells/injection}) injected into SCID mice either alone, with MSCshsc or with MSCshcox-2 (2 \times 10^5 \text{ cells/injection}). Filled circles indicate individual tumor weights; Open circles indicate no tumor grew at the site of injection. Bars are means \pm SE.

**Fig. 6. PGE_2 induces ALDH^{high} cancer cells through the Akt/GSK-3/\beta-catenin signaling axis.** (A) Activation of Akt/GSK3/\beta-catenin signaling in LoVo cells treated as indicated for one hour was analyzed by Western blots for phosphorylated Akt, total Akt, phosphorylated GSK-3\alpha, phosphorylated GSK-3\beta, total GSK-3\beta, phosphorylated \beta-catenin, total \beta-catenin and GAPDH. The numbers indicate relative protein levels. (B) The distribution of E-cadherin (red), ZO-1 (green) and \beta-catenin (red) in LoVo cells treated with vehicle or PGE_2 (100 nM) for 48 h was analyzed by immunofluorescence. Cell nuclei were stained with DAPI (in blue). The graphs show the fluorescence intensities along the dashed lines in the images of \beta-catenin staining. \beta-catenin intensities are in red lines and DAPI intensities are in blue lines. (C) Quantification of the levels of E-cadherin, ZO-1 and \beta-catenin associated with membrane and of nuclear \beta-catenin. The fluorescence intensities for the staining of these proteins in randomly selected cells in images (e.g. the cells crossed by dashed lines in panel B) were quantified. Bars are means \pm SE, n > 50 for each bar. M \beta-catenin: membrane-bound \beta-catenin. N \beta-catenin; nuclear \beta-catenin. (D) Nuclear/cytosolic distribution of \beta-catenin in LoVo cells treated as indicated was analyzed by Western blot of \beta-catenin, GAPDH, and lamin B1, a nuclear envelope marker, in nuclear and cytosolic fractions. (E) mRNA expression of selected \beta-catenin/TCF dependent genes in LoVo cells treated with
vehicle or PGE$_2$ for 7 h. The mRNA levels of these genes were normalized to GAPDH mRNA. Data are fold induction by PGE$_2$ (vs that of vehicle-treated LoVo cells). Data are means ± SE, n = 3. (F) ALDH activities of ALDH$^{\text{high}}$ LoVo cells treated with vehicle, PGE$_2$, PGE$_2$ + GW627368X (GW; 20 μM), PGE$_2$ + LY294002 (0.5 μM) or PGE$_2$ + FH535 (6 μM) for 5 days (a-c). Percentages of ALDH$^{\text{high}}$ LoVo cells are presented in the table (d). The gray lines at the right side of the plots indicate the thresholds of the high ALDH activity.

Fig. 7. MSCs in tumor stroma serve as an ALDH$^{\text{high}}$ cancer stem cell niche. (A) Immunofluorescence analyses were performed on tumors derived from LoVo cells (5 × 10$^4$ cells/injection) injected along with tdTomato-MSCs (5 × 10$^5$ cells/injection), using antibodies against tdTomato-RFP (in green), ALDH1 (in red, panel a), Fibroblast Surface Protein FSP (in red, panel b), and COX2 (cyan). Panels a and b are serial sections from one tumor. (B) IL-1 and COX2 mRNA expression in human colon and breast carcinoma. The “Fold Change” indicates the average mRNA levels of the three genes in colon mucinous carcinoma samples, compared to that of normal colon samples (panel a) and in TNBC samples, compared to that of non-TNBC samples (panel b). (C) The proposed interactions for induction and maintenance of EMT, cancer cell stemness and invasiveness by MSCs. AA: arachidonic acid
**Fig. 1**

A. Graph showing PGE2 levels (ng/ml) over time (h) for different cell lines: LoVoMSC, LoVo, MSC, SW116MSC, and SW116.

B. Bar graphs depicting PGE2 levels (ng/ml) for different conditions:
   - (a) LoVo vs. LoVo + anti-IL-1α
   - (b) LoVo/MSC vs. LoVo/MSC + anti-IL-1α
   - (c) LoVo/MSC + 100 ng/ml IL-1α vs. LoVo/MSC + 100 ng/ml IL-1α

C. Graphs illustrating IL-1α, IL-1β, and IL-1ra levels in CM (pg/ml):
   - (a) HCC1986, BT549, SUM149, SUM159, MDA-MB-231, and SW116
   - (b) HCC1986, BT549, SUM149, SUM159, MDA-MB-231, and SW116

Western blots showing COX2 and GAPDH levels.

* p < 0.05, ** p < 0.001, *** p < 0.005
**Fig. 2**

A. **Relative expression of soluble factor**

- PGE$_2$
- GRO-α
- IL-6
- IL-8
- RANTES

**LoVoMSC**
- [LoVo][MSC]
- SW1116MSC
- MSC
- LoVo
- SW1116

**p < 0.01, ***p < 0.005**, compared to MSC culture

B. **mRNA level by qPCR (Target gene: GAPDH)**

- COX2
- mPGES1
- 15-PGDH
- IL-6
- IL-8
- Gro-α

**Control**
- IL1-α
- IL1-β
- IL1-α + IL1-β

**p < 0.05, ***p < 0.005**, compared to control

C. **Cytokine level (ng/mL)**

- GRO-α
- IL-6
- IL-8

**LoVo**
- MSC
- Indo
- PGE$_2$

**p < 0.006**

D. **mRNA induction (percent compared to level with LoVoCM or IL-1)**

- LoVoCM + EP2/4 antagonist
- IL-1 + EP2/4 antagonist

**IL-6**
- IL-8
- GRO-α

**p < 0.05, **p < 0.01, ***p < 0.005**, MSC treated with LoVoCM or IL-1 only.
Fig. 5
Fig. 6
Figure 7

A. dTomato (MSC) and ALDH1, COX-2

B. Gene expression analysis for COX2, IL1α, and IL1β in colon and breast samples.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Fold Change</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>COX2</td>
<td>5.35</td>
<td>7.77E-9</td>
</tr>
<tr>
<td>IL1α</td>
<td>9.57</td>
<td>4.60E-11</td>
</tr>
<tr>
<td>IL1β</td>
<td>4.66</td>
<td>6.23E-8</td>
</tr>
</tbody>
</table>

(1) 22 colon mucinous carcinoma
(2) 101 colon carcinoma
(3) 19 normal colon samples
(4) 25 human triple negative breast carcinoma
(5) 153 non-triple negative breast carcinoma samples

C. Diagram showing the interaction between LaVo Cell and MSC, involving EMT, invasion, and stemness markers.
Cancer-stimulated mesenchymal stem cells create a carcinoma stem-cell niche via Prostaglandin E2 signaling

Hua-Jung Li, Ferenc Reinhardt, Harvey R. Herschman, et al.

Cancer Discovery Published OnlineFirst July 3, 2012.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/2159-8290.CD-12-0101</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://cancerdiscovery.aacrjournals.org/content/suppl/2012/06/27/2159-8290.CD-12-0101.DC1">http://cancerdiscovery.aacrjournals.org/content/suppl/2012/06/27/2159-8290.CD-12-0101.DC1</a></td>
</tr>
<tr>
<td>Author Manuscript</td>
<td>Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.</td>
</tr>
</tbody>
</table>